- Home
- SNDL vs RGNX Comparison
SNDL vs RGNX Comparison
Compare SNDL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDL
- RGNX
- Stock Information
- Founded
- SNDL 2006
- RGNX 2008
- Country
- SNDL Canada
- RGNX United States
- Employees
- SNDL N/A
- RGNX N/A
- Industry
- SNDL Pharmaceuticals and Biotechnology
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNDL Health Care
- RGNX Health Care
- Exchange
- SNDL Nasdaq
- RGNX Nasdaq
- Market Cap
- SNDL 357.7M
- RGNX 424.8M
- IPO Year
- SNDL 2019
- RGNX 2015
- Fundamental
- Price
- SNDL $2.02
- RGNX $8.10
- Analyst Decision
- SNDL
- RGNX Strong Buy
- Analyst Count
- SNDL 0
- RGNX 8
- Target Price
- SNDL N/A
- RGNX $28.50
- AVG Volume (30 Days)
- SNDL 3.7M
- RGNX 610.1K
- Earning Date
- SNDL 07-31-2025
- RGNX 08-07-2025
- Dividend Yield
- SNDL N/A
- RGNX N/A
- EPS Growth
- SNDL N/A
- RGNX N/A
- EPS
- SNDL N/A
- RGNX N/A
- Revenue
- SNDL $692,339,389.00
- RGNX $155,782,000.00
- Revenue This Year
- SNDL $4.13
- RGNX $327.08
- Revenue Next Year
- SNDL $4.44
- RGNX N/A
- P/E Ratio
- SNDL N/A
- RGNX N/A
- Revenue Growth
- SNDL 3.54
- RGNX 74.95
- 52 Week Low
- SNDL $1.15
- RGNX $5.04
- 52 Week High
- SNDL $2.40
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- SNDL 76.22
- RGNX 45.90
- Support Level
- SNDL $1.64
- RGNX $7.35
- Resistance Level
- SNDL $1.84
- RGNX $8.48
- Average True Range (ATR)
- SNDL 0.10
- RGNX 0.46
- MACD
- SNDL 0.04
- RGNX -0.08
- Stochastic Oscillator
- SNDL 83.10
- RGNX 38.07
About SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.